Abstract: A method and apparatus for estimating execution time of a neural network are provided, the method of estimating execution time of a neural network in a multi-core accelerator, the method including generating trace information including operation timing information for each core of the multi-core accelerator, and calculating the execution time of the neural network reflecting communication overhead between cores of the multi-core accelerator and memory access time for each core of the cores, based on the trace information.

Abstract: An implantable medical device (IMD) charger apparatus may include an IMD charger including a housing defining a bottom surface, a primary coil located within the housing, and a fastener on the bottom surface of the housing, and a charger support, mounted on the IMD charger, including a bottom surface, and movable between a first state and a second state. The IMD charger and the charger support may be respectively configured such that the IMD charger fastener is above the charger support bottom surface when the charger support is in the first state and the IMD charger fastener is at or below the charger support bottom surface when the charger support is in the second state.

Abstract: The disclosure provides a chondrocyte cell sheet comprising one or more layers of confluent cells comprising chondrocytes and chondroprogenitor cells. Methods of generating cartilage tissue in a subject are also provided. The disclosure also provides a method for producing chondrocyte cell sheets comprising culturing chondrocytes and chondroprogenitor cells in culture solution on a temperature-responsive polymer which has been coated onto a substrate surface of a cell culture support, wherein the temperature-responsive polymer has a lower critical solution temperature in water of 0-80° C.; adjusting the temperature of the culture solution to below the lower critical solution temperature, whereby the substrate surface is made hydrophilic and adhesion of the cell sheet to the surface is weakened; and detaching the cell sheet from the culture support.

Abstract: Disclosed is a 3-terminal neuromorphic synaptic device including a substrate, a source electrode and a drain electrode provided on the substrate to be spaced apart from each other, a channel area provided on the substrate to be electrically connected to the source electrode and the drain electrode, between the source electrode and the drain electrode, an ion transport layer provided on the channel area, a gate electrode provided on the ion transport layer, and a voltage application part that applies a gate voltage to the gate electrode. The gate electrode is formed of at least one of an oxide-based material including mobile ions, a chalcogenide-based material including the mobile ions, and a nitride-based material including the mobile ions.

Abstract: Disclosed are a personalized sleep planning system that finds and recommends an optimal sleep/bedtime and wakeup time using user data such as a user’s schedule and bio-rhythm information, and a method of creating a sleep schedule for the same. The sleep planning system comprises: a recommended sleep schedule generator for determining a sleep pressure based on first user data including a personal schedule obtained from a user device and generating a recommended sleep schedule based on the sleep pressure with respect to constraints based on the personal schedule; and an output processing unit for updating the personal schedule of a calendar of the user device with the recommended sleep schedule or providing information related to the recommended sleep schedule to the user device.

Abstract: One aspect relates to a pharmaceutical composition for the prevention or treatment of cancer or an anticancer immune vaccine composition, including a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1. The composition can enhance anticancer immunity by activating dendritic cells and T cells, and furthermore, can exhibit a remarkably excellent synergistic anticancer immune effect through administration in combination with an immune checkpoint inhibitor.

Abstract: A semiconductor device may include an active pattern on a substrate, a lower channel pattern on the active pattern and including first and second lower semiconductor patterns, an upper channel pattern on the lower channel pattern and including first and second upper semiconductor patterns, a pair of lower source/drain patterns on opposite sides of the lower channel pattern and a pair of upper source/drain patterns on opposite sides of the upper channel pattern, and a gate electrode surrounding the lower and upper channel patterns. The gate electrode may include a first upper portion between the first and second upper semiconductor patterns, and a first lower portion between the first and second lower semiconductor patterns. Each semiconductor pattern may include a first recess part having a first recess region on a top surface thereof, and a first protrusion part protruding from a bottom surface of the first recess part.

Abstract: A drug injection control device generates a policy model by learning a change in anesthetic state information due to a drug injection rate set so that anesthetic state information of a patient follows target anesthetic state information, generates a prediction model by learning a change in the anesthetic state information according to a change in the drug injection rate, sets the drug injection rate from the anesthetic state information based on the policy model, and predicts expected anesthetic state information from the set drug injection rate and a previously set drug injection rate based on the prediction model.

Abstract: The present invention relates to a composition for preventing or treating liver disease, comprising icaritin and quercetin. It is ascertained that when icaritin and quercetin are used in combination rather than individually, the composition of the present invention has a superior effect of hepatic cell protection, and the optimal mixing ratio is derived, and it is also ascertained that the composition exhibits hepatoprotective action and does not induce toxicity in normal cells, and thus the present invention can be used as an active ingredient of a therapeutic agent for liver disease or a health functional food for preventing liver disease.

Abstract: An assay device includes an electrochemical testing assembly having a test channel including a capture reagent selected to capture a target analyte and an electrode having a surface in communication with the test channel. The assay device further includes a microfluidic network in communication with the test channel, a buffer fluid inlet in communication with the microfluidic network, and a detection reagent disposed within the microfluidic network. When a buffer fluid is provided to the buffer fluid inlet, the buffer fluid transports the detection reagent to the test channel by capillary-driven flow, and wherein the electrode is configured to measure an electrical response indicating capture of the target analyte by the capture reagent after transportation of the detection reagent to the test channel.

Abstract: A photochemical reactor is disclosed which includes a reaction chamber, the reaction chamber includes a frame, one or more circuit boards each coupled to the frame and each carrying a plurality of light sources, a power source coupling, adapted to power the one or more circuit boards, and a vial receiver centrally disposed about the one or more circuit boards. The photochemical reactor further includes an agitator configured to rotate the vial receiver.

Abstract: The present invention relates to a 3-((8-((1H-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethynyl)-N-phenylbenzamide derivative, a method for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating cancer. The derivative can significantly inhibit the proliferation of cancer cells by inhibiting kinases, particularly Bcr-Abl kinase or Bcr-Abl (T315I) kinase. Therefore, the derivative can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer.

Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.

Abstract: The present invention relates to a molten salt-metal reactor for implementing a micro-reactor, and more specifically, to a molten salt-metal reactor including a liquid metal nuclear fuel and a molten salt coolant, wherein the molten salt coolant is disposed in an upper portion of the liquid metal nuclear fuel such that the heat generated from the nuclear fuel is transferred to the molten salt coolant and cooled.

Abstract: A neural network method and device are included, A neural network circuit includes a synaptic memory cell including a resistive memory element, which is disposed along an output line and which can have a first resistance value and a second resistance value as a resistance value, the synaptic memory cell generates a column signal, based on the resistance value of the resistive memory element and an input signal received via an input line, a reference memory cell including a reference memory element, which is disposed along a reference line and which has a resistance value that is a ratio of the first and second resistance values, the reference memory cell generates a reference signal, based on the resistance value of the reference memory element and the input signal, and an output circuit generates an output signal for the output line based on the column signal and the reference signal.

Abstract: A stabilized Ace2 variant has a disulfide bond introduced by substituting cysteine for amino acid residue pairs at specific positions of the Ace2 protein, thereby having excellent stability. The stabilized Ace2 variant exhibits high binding affinity for SARS-CoV-2 virus and excellent stability even in an aqueous solution condition. When the stabilized Ace2 variant is applied to a therapeutic agent for COVID-19, which is the SARS-CoV-2 infectious disease, the shelf stability, in-vivo stability, and therapeutic effect of the therapeutic agent may all be improved. In addition, since it uses the amino acid sequence derived from the receptor for SARS-CoV-2, it may effectively work even against various virus mutant strains.

Abstract: A method can include milling a powder with a test grinding media, and determining an amount of abraded grinding media that abrades from the test grinding media into the powder due to the milling of the powder. The method can include creating a compensated powder to account for the amount of the abraded grinding media such that the powder milling process results in a desired powder composition.

Abstract: The present invention generally relates to a pharmaceutical formulation that substantially increases the bioavailability of niclosamide or a pharmaceutically acceptable salt thereof for a variety of routes of delivery for therapeutic purposes. The newly enhanced formulation also substantially expands the potential therapeutic applications of niclosamide. Pharmaceutical compositions and methods of uses thereof are within the scope of this disclosure.

Abstract: This disclosure relates to an intermolecularly-fabricated composition for capturing plant materials, agrochemicals and pharmaceuticals which can simultaneously capture inorganic particulates and organic compounds in which the capture materials have mutual chemical affinity with the composition matrix thereby exhibiting an adhesive property.

Abstract: There is provided a multi-scale object detection device. The device includes an image frame acquisition unit for acquiring a plurality of consecutive image frames, a critical region extractor for extracting at least one second critical region from a current image frame based on at least one first critical region extracted from a previous image frame among the consecutive image frames, a multi-scale object detector whose operation involves a first object detection process for the current image frame and a second object detection process for the at least one second critical region, and an object detection integration unit for integrating the results of the first and second object detection processes.